🔥🐔 BizChicken 🐔🔥

Companies Similar to Aldeyra Therapeutics, Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics, Inc. logo
Market Cap: Low
Employees: Lowest

reproxalap

Aldeyra Therapeutics, Inc. is a biotechnology company that develops and commercializes medicines for immune-mediated ocular and systemic diseases, with lead product candidate reproxalap in Phase III clinical trials.

Tags: biotechnology, clinical trials, immune-mediated diseases, ocular diseases, systemic diseases

Symbol: ALDX

Recent Price: $5.02

Industry: Biotechnology

CEO: Dr. Todd C. Brady M.D., Ph.D.

Sector: Healthcare

Employees: 10

Address: 131 Hartwell Avenue, Lexington, MA 02421

Phone: 781 761 4904

Leadership

  • Todd C. Brady, M.D., Ph.D., Chief Executive Officer, President & Director
  • Stephen G. Machatha, Ph.D., Chief Development Officer
  • Caitlin Pazzano, Vice President, Quality Assurance
  • Bill Cavanagh, Vice President, Clinical Operations
  • Neal Walker, D.O., Director
  • Gary Phillips, M.D., M.B.A., Director
  • Nancy Miller-Rich, Director
  • Martin J. Joyce, M.B.A., Director
  • Ben Bronstein, M.D., Director
  • Richard H. Douglas, Ph.D., Chairman of the Board

Last updated: 2024-12-31

Allakos Inc.

Allakos Inc. logo
Market Cap: Lowest
Employees: Low

lirentelimab (AK002)

Allakos Inc. is a clinical stage biopharmaceutical company that develops therapeutics targeting immunomodulatory receptors on immune cells for allergy, inflammatory, and proliferative diseases.

Tags: allergy, biopharmaceutical, immunomodulatory, inflammatory diseases, therapeutics

Symbol: ALLK

Recent Price: $1.19

Industry: Biotechnology

CEO: Dr. Robert Alexander Ph.D.

Sector: Healthcare

Employees: 131

Address: 975 Island Drive, Redwood City, CA 94065

Phone: 650 597 5002

Leadership

  • Robert Alexander, PhD, Chief Executive Officer
  • Robert Andreatta, CFA, Vice President, Controller
  • Neil Graham, MD, Chief Medical Officer
  • Steven James, Biopharma Executive
  • Amy Ladd, MD, Professor of Orthopaedic Surgery
  • Dolca Thomas, MD, Venture Partner
  • Paul Walker, CFA, Partner

Last updated: 2024-12-31

Alector, Inc.

Alector, Inc. logo
Market Cap: Medium
Employees: Low

AL001, AL101, AL002, AL003, AL044

Alector, Inc. is a clinical stage biopharmaceutical company focused on developing therapies for neurodegeneration diseases. The company has several products in various stages of clinical trials aimed at treating conditions such as Alzheimer's, Parkinson's, and frontotemporal dementia.

Tags: Alzheimer's, Parkinson's, biopharmaceutical, clinical trials, neurodegeneration, therapies

Symbol: ALEC

Recent Price: $1.72

Industry: Biotechnology

CEO: Dr. Arnon Rosenthal Ph.D.

Sector: Healthcare

Employees: 245

Address: 131 Oyster Point Boulevard, South San Francisco, CA 94080

Phone: 415 231 5660

Leadership

  • Arnon Rosenthal, Ph.D., Co-Founder, Chief Executive Officer, and Director
  • Sara Kenkare-Mitra, Ph.D., President and Head of Research and Development
  • Marc Grasso, M.D., Chief Financial Officer
  • Gary Romano, M.D., Ph.D., Chief Medical Officer
  • Danielle Pasqualone, Ph.D., J.D., General Counsel
  • Clare Hunt, M.B.A., Chief People Officer
  • Kristina Cutter, M.P.H., Chief Regulatory, Pharmacovigilance, and Quality Assurance Officer
  • Virginia DeJesus-Rueff, M.B.A., Chief of Staff and Head of Strategy
  • Norah Conway, Senior Vice President, Portfolio and Program Management
  • Neil Berkley, M.S., M.B.A., Chief Business Officer
  • Louis J. Lavigne Jr., M.B.A., Chairperson of the Board
  • Elizabeth Garofalo, M.D., Board Member
  • Paula Hammond, Ph.D., Board Member
  • Richard H. Scheller, Ph.D., Board Member
  • David Wehner, Board Member
  • Kristine Yaffe, M.D., Board Member
  • Errol De Souza, Ph.D., Board Member
  • Mark Altmeyer, M.B.A., Board Member

Last updated: 2024-12-31

DURECT Corporation

DURECT Corporation logo
Market Cap: Lowest
Employees: Lowest

ALZET

DURECT Corporation is a biopharmaceutical company that develops medicines based on its epigenetic regulator and pharmaceutical programs. It offers products like ALZET osmotic pumps for laboratory animal research, larsucosterol for treating liver diseases, and POSIMIR for post-surgical pain relief.

Tags: ALZET, POSIMIR, biopharmaceutical, epigenetic, larsucosterol, research

Symbol: DRRX

Recent Price: $0.85

Industry: Drug Manufacturers - Specialty & Generic

CEO: Dr. James E. Brown D.V.M.

Sector: Healthcare

Employees: 48

Address: 10260 Bubb Road, Cupertino, CA 95014-4166

Phone: 408 777 1417

Last updated: 2024-12-31

Lyra Therapeutics, Inc.

Lyra Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Low

XTreo technology platform

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company developing integrated drug and delivery solutions for ear, nose, and throat diseases using its XTreo technology platform. It focuses on product candidates like LYR-210 and LYR-220 for chronic rhinosinusitis.

Tags: biotechnology, chronic rhinosinusitis, drug delivery, healthcare, therapeutics

Symbol: LYRA

Recent Price: $0.22

Industry: Biotechnology

CEO: Dr. Maria Palasis Ph.D.

Sector: Healthcare

Employees: 88

Address: 480 Arsenal Way, Watertown, MA 02472

Phone: 617 393 4600

Leadership

  • Harlan W. Waksal, M.D., Executive Chairman
  • Maria Palasis, Ph.D., President and Chief Executive Officer
  • Jason Cavalier, Chief Financial Officer
  • Robert Kern, M.D., Chief Clinical Advisor
  • Ronan O’Brien, Chief Legal Officer
  • Vineeta Belanger, Ph.D., Senior Vice President of Clinical Affairs
  • Gloria Cosgrove, Senior Vice President of Quality
  • Allison Nance, Senior Vice President of Regulatory Affairs
  • Michael Altman, CFA, Managing Director, Perceptive Advisors
  • Ann Merrifield, Life Sciences Advisor and Board Director
  • Konstantin Poukalov, Managing Director, Perceptive Advisors
  • Bradford Smith, Board Director
  • Nancy L. Snyderman, M.D., Board Director
  • Jim Tobin, Lead Independent Director
  • Robert Langer, D.Sc., David H. Koch Institute Professor, Massachusetts Institute of Technology
  • George Whitesides, Ph.D., Woodford L. and Ann A. Flowers University Professor, Harvard University

Last updated: 2024-12-31

Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. logo
Market Cap: Highest
Employees: Highest

EYLEA, Dupixent, Libtayo, Praluent, REGEN-COV, Kevzara, Inmazeb

Regeneron Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes medicines for treating various diseases worldwide, including treatments like EYLEA, Dupixent, Libtayo, and more.

Tags: biotechnology, diseases, healthcare, injections, medicines, pharmaceuticals, treatment

Symbol: REGN

Recent Price: $702.59

Industry: Biotechnology

CEO: Dr. Leonard S. Schleifer M.D., Ph.D.

Sector: Healthcare

Employees: 14165

Address: 777 Old Saw Mill River Road, Tarrytown, NY 10591-6707

Phone: 914 847 7000

Leadership

  • Leonard S. Schleifer, MD, PhD, Board co-Chair, President and Chief Executive Officer
  • George D. Yancopoulos, MD, PhD, Board co-Chair, President and Chief Scientific Officer
  • Zoran Berkovic, Senior Vice President, Financial Planning and Analysis
  • Maya Bermingham, Senior Vice President, Public Policy and Government Affairs
  • Leonard Brooks, Senior Vice President, Treasurer
  • John Calabro, Senior Vice President, Internal Audit
  • Christina Chan, Senior Vice President, Corporate Affairs
  • Larry Coury, PhD, Senior Vice President, Associate General Counsel
  • Ryan Crowe, Senior Vice President, Investor Relations & Strategic Analysis
  • Matthew Everett, Senior Vice President, Global Procurement
  • Chris Fenimore, Senior Vice President, Finance and Chief Financial Officer
  • Rick Hall, Senior Vice President, Human Resources
  • Justin Holko, Senior Vice President, Global Oncology/Hematology Commercial Business Unit
  • Nouhad Husseini, Senior Vice President, Business Development
  • Joseph J. LaRosa, Executive Vice President, General Counsel and Secretary
  • Melissa Lozner, Senior Vice President, Chief Compliance Officer
  • Marion McCourt, Executive Vice President, Commercial
  • Bob McCowan, Senior Vice President, IT and Chief Information Officer
  • Gonzalo Merino, PhD, Senior Vice President, Chief Intellectual Property Counsel and Associate General Counsel
  • Richard O’Neal, Senior Vice President, Market Access
  • Sally A. Paull, Executive Vice President, Human Resources
  • Smita Pillai, Senior Vice President, Culture and DEI and Chief DEI Officer
  • George Poth, Senior Vice President, Real Estate & Facilities Management
  • Alessandra Ravetti, Senior Vice President, Associate General Counsel
  • Kerry Reinertsen, PhD, Senior Vice President, Strategic Alliances
  • David Snow, Senior Vice President, Global Head, Dupixent Franchise
  • Mark Volpe, Senior Vice President, Tax
  • Bola Akinlade, MD, FACP, Senior Vice President, Clinical Development, Immunology and Inflammation
  • Hanne Bak, PhD, Senior Vice President, Preclinical Manufacturing and Process Development
  • Aris Baras, MD, Senior Vice President, Regeneron Genetics Center®
  • Ned Braunstein, MD, Executive Vice President, Regulatory Affairs and Global Patient Safety
  • Gang Chen, PhD, Senior Vice President, Protein Expression Sciences
  • Thomas DiCioccio, PhD, Senior Vice President, Pharmacometrics
  • Benjamin Drosman, Senior Vice President, Global Development Quality & Regulatory Compliance
  • Gregory Geba, MD, PhD, Senior Vice President, Global Development Scientific Council
  • Philip Gregory, DPhil, Senior Vice President, Regeneron Cell Medicines
  • Gary Herman, MD, Senior Vice President, Early Clinical Development and Experimental Sciences
  • Boaz Hirshberg, MD, Senior Vice President, Clinical Sciences General Medicine
  • Diana Hughes, MBBS, Senior Vice President, Global Patient Safety
  • Bari Kowal, Senior Vice President, Development Operations and Portfolio Management
  • Christos Kyratsous, PhD, Senior Vice President, Research
  • Johnathan Lancaster, MD, PhD, Senior Vice President, Global Medical Affairs
  • John Lin, MD, PhD, Senior Vice President, Immuno-Oncology and Head of Bispecifics
  • Israel Lowy, MD, PhD, Senior Vice President, Translational and Clinical Sciences, Oncology
  • Lynn Macdonald, PhD, Senior Vice President, Research
  • Lori Morton, PhD, Senior Vice President, Research
  • Andrew Murphy, PhD, Executive Vice President, Research
  • Muriel O'Byrne, PhD, Senior Vice President, International Regulatory Affairs & Head, European Business Office
  • William Olson, PhD, Senior Vice President, Therapeutic Proteins
  • Mohammed Shameem, PhD, Senior Vice President, Formulations Development
  • L. Andres Sirulnik, MD, PhD, Senior Vice President, Translational and Clinical Sciences, Hematology
  • Randy Soltys, PhD, Senior Vice President, Drug Safety and Pharmacometrics
  • Neil Stahl, PhD, Executive Vice President, Research and Development
  • Robert Vitti, MD, Senior Vice President, Clinical Trial Excellence Strategy
  • Brian Zambrowicz, PhD, Executive Vice President, Functional Genomics and Chief VelociGene® Operations
  • Rajesh Ahuja, Senior Vice President, Fill/Finish and External Manufacturing
  • Frederick Austin, Senior Vice President, Quality Control, Raheen
  • Christine Childrose, Senior Vice President, Human Resources and HR Operations
  • David Crenshaw, Senior Vice President, Associate General Counsel
  • Tikiri Dissanayake, Senior Vice President, IOPS Technical Operations
  • Patrice Gilooly, Senior Vice President, Quality Assurance and Operations
  • Jennifer McNay, PhD, Senior Vice President, CMC Regulatory Sciences and Industrial Affairs
  • Niall O’Leary, Senior Vice President and Site Head, IOPS Raheen
  • Scott Oberman, Senior Vice President, Supply Chain Operations
  • David Simon, Senior Vice President, IOPS Finance and Business Operations
  • Daniel Van Plew, Executive Vice President and General Manager, Industrial Operations and Product Supply
  • Benjamin Yocum, Senior Vice President, Manufacturing Operations
  • James Wolfe, Senior Vice President, Process Sciences and Drug Product Engineering
  • Bonnie L. Bassler, PhD, Director
  • Michael S. Brown, MD, Director
  • N. Anthony Coles, MD, Chair of the Board
  • Joseph L. Goldstein, MD, Director
  • Kathryn Guarini, PhD, Director
  • Christine A. Poon, Lead Independent Director
  • Arthur F. Ryan, Director
  • Huda Y. Zoghbi, MD, Director
  • Samantha Dickon, Director, Development Program Management
  • Gervasio Batista, Sr. Scientist, Neuroscience
  • James K. Gibson, Senior Regional Director, Immunology/Pulmonary
  • Beth Brause, Director, Field Reimbursement Management
  • Eric Prendergast, Director, Pricing Strategy
  • Ashley Neff, Manager, Digital Communications
  • Shari Loock, Associate Director, Sourcing
  • Jennifer Davidson Hamilton, VP and Head of Precision Medicine
  • Yi Zhang, Director, Health Economics & Outcomes Research
  • Wilson Caldwell III, Director, GCO Vendor & Relationship Management
  • David Stein, Director, Medical Operations
  • Regeneron, Corporate
  • Grant Anicete, Biotech Production Specialist I / IOPS Rensselaer
  • Mary McKenna, Lead Quality Control Analyst / IOPS Raheen
  • Ashley Lebby, Lead Senior Biotech Production Specialist / IOPS Rensselaer
  • Varenka Rodriguez Diblasi, Principal Scientist, Bioinformatics
  • Jessie Brown, Manager, Integrative Translational Genetics
  • Gisu Eom, Lead Cloud DevOps Engineer
  • Carmen Kenworthy, Scientist, Velocigene
  • Ralph Hazlewood, Sr. Manager, Research Program Management
  • Brandy Bennett, Sr. Director, R&D Strategy & Operations

Last updated: 2024-12-31

Revelation Biosciences, Inc.

Revelation Biosciences, Inc. logo
Market Cap: Lowest
Employees: Lowest

REVTx-99b

Revelation Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing immune system therapeutics and diagnostics, including products for chronic nasal congestion, allergic rhinitis, chronic organ disease, and viral infections.

Tags: allergic rhinitis, biopharmaceutical, clinical trial, diagnostics, immune system therapeutics, kidney disease, nasal congestion, viral infections

Symbol: REVB

Recent Price: $0.39

Industry: Biotechnology

CEO: Mr. James M. Rolke

Sector: Healthcare

Employees: 9

Address: 4660 La Jolla Village Drive, San Diego, CA 92122

Phone: 650-800-3717

Last updated: 2024-12-31

Reneo Pharmaceuticals, Inc.

Reneo Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

REN001

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on developing therapies for patients with rare genetic mitochondrial diseases. Its primary product, REN001, is a selective peroxisome proliferator-activated receptor delta agonist currently in clinical trials.

Tags: Clinical Trials, Genetic Disorders, Mitochondrial Diseases, Pharmaceuticals, Therapeutics

Symbol: RPHM

Recent Price: $18.20

Industry: Biotechnology

CEO: Mr. Gregory J. Flesher

Sector: Healthcare

Employees: 8

Address: 18575 Jamboree Road, Irvine, CA 92612

Phone: 619 733 3852

Last updated: 2024-12-31

Spyre Therapeutics, Inc.

Spyre Therapeutics, Inc. logo
Market Cap: High
Employees: Lowest

antibody therapeutics

Spyre Therapeutics, Inc. is a biotechnology company focusing on antibody therapeutics for treating inflammatory bowel disease, using advanced engineering and precision medicine.

Tags: antibody therapeutics, biotechnology, inflammatory bowel disease, precision medicine

Symbol: SYRE

Recent Price: $22.54

Industry: Biotechnology

CEO: Dr. Cameron Turtle DPHIL, Ph.D.

Sector: Healthcare

Employees: 50

Address: 221 Crescent Street, Waltham, MA 02453

Phone: 617 651 5940

Last updated: 2024-12-31

Aileron Therapeutics, Inc.

Aileron Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

ALRN-6924

Aileron Therapeutics, Inc. is a clinical stage oncology company developing ALRN-6924 for various cancer treatments, with multiple clinical trials in progress.

Tags: ALRN-6924, cancer therapies, chemoprotection, clinical stage, clinical trials, oncology

Symbol: ALRN

Recent Price: $2.32

Industry: Biotechnology

CEO: Dr. James Brian Windsor Ph.D.

Sector: Healthcare

Employees: 15

Address: 285 Summer Street, Boston, MA 02210

Phone: 617 995 0900

Last updated: 2024-12-31

Ardelyx, Inc.

Ardelyx, Inc. logo
Market Cap: High
Employees: Low

tenapanor

Ardelyx, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for gastrointestinal and cardiorenal therapeutic areas, including treatments for irritable bowel syndrome with constipation and hyperphosphatemia.

Tags: CKD, biopharmaceutical, cardiorenal, gastrointestinal, hyperkalemia, hyperphosphatemia, metabolic acidosis, tenapanor

Symbol: ARDX

Recent Price: $5.25

Industry: Biotechnology

CEO: Mr. Michael G. Raab

Sector: Healthcare

Employees: 267

Address: 400 Fifth Avenue, Waltham, MA 02451

Phone: 510 745 1700

Leadership

  • Justin Renz, Chief Financial & Operations Officer
  • Eric Foster, Chief Commercial Officer
  • Elizabeth Grammer, Esq., Chief Legal & Administrative Officer
  • Laura Williams, MD MPH, Chief Medical Officer
  • Robert Blanks, MS RAC, Chief Regulatory Affairs & Quality Assurance Officer
  • David Rosenbaum, PhD, Chief Development Officer
  • Mike Kelliher, Executive Vice President, Corporate Development and Strategy
  • Charon Spencer, Chief Human Resources Officer
  • David Mott, Chairman
  • Robert Bazemore, Director
  • William A. Bertrand, Jr., JD, Director
  • Muna Bhanji, R.Ph, Director
  • Onaiza Cadoret-Manier, Director
  • Mike Raab, Director
  • Richard Rodgers, Director

Last updated: 2024-12-31

BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc. logo
Market Cap: High
Employees: Medium

ORLADEYO

Bio Cryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering novel, oral, and small-molecule medicines, with marketed products including RAPIVAB and ORLADEYO, and a pipeline featuring BCX9930, BCX9250, and Galidesivir.

Tags: biotechnology, clinical trials, hereditary angioedema, influenza treatment, oral medicines, small-molecule medicines

Symbol: BCRX

Recent Price: $7.53

Industry: Biotechnology

CEO: Mr. Jon P. Stonehouse

Sector: Healthcare

Employees: 536

Address: 4505 Emperor Boulevard, Durham, NC 27703

Phone: 919 859 1302

Last updated: 2024-12-31

Eton Pharmaceuticals, Inc.

Eton Pharmaceuticals, Inc. logo
Market Cap: Low
Employees: Lowest

Biorphen, Carglumic Acid, Rezipres, Alkindi Sprinkle, EPRONTIA, Alaway Preservative Free

Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for rare diseases, with a portfolio including treatments like Biorphen, Carglumic Acid, and others for various indications.

Tags: Alaway Preservative Free, Alkindi Sprinkle, Biorphen, Carglumic Acid, EPRONTIA, Pharmaceuticals, Rare Diseases, Rezipres

Symbol: ETON

Recent Price: $13.03

Industry: Biotechnology

CEO: Mr. Sean E. Brynjelsen

Sector: Healthcare

Employees: 30

Address: 21925 West Field Parkway, Deer Park, IL 60010-7208

Phone: 847 787 7361

Last updated: 2024-12-31

Kiora Pharmaceuticals, Inc.

Kiora Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

KIO-301

Kiora Pharmaceuticals, Inc. develops therapies for ophthalmic diseases, with lead product KIO-301 in Phase 1 trial for vision restoration in degenerative retinal diseases and other products in trials for conditions like rheumatoid arthritis-related ocular issues and corneal wound repair.

Tags: clinical trials, ophthalmic diseases, ophthalmology, pharmaceuticals, vision restoration

Symbol: KPRX

Recent Price: $3.30

Industry: Biotechnology

CEO: Dr. Brian M. Strem Ph.D.

Sector: Healthcare

Employees: 12

Address: 1371 East 2100 South, Salt Lake City, UT 84105

Phone: 781 788 8869

Last updated: 2024-12-31

Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc. logo
Market Cap: High
Employees: Low

novel small molecule therapeutics

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system.

Tags: IRAK4 program, autoimmune diseases, biopharmaceutical, immunology, inflammation, oncology, protein degradation, therapeutics

Symbol: KYMR

Recent Price: $39.32

Industry: Biotechnology

CEO: Dr. Nello Mainolfi M.D., Ph.D.

Sector: Healthcare

Employees: 184

Address: 200 Arsenal Yards Boulevard, Watertown, MA 02472

Phone: 857 285 5300

Leadership

  • Nello Mainolfi, Ph.D., Founder, President & CEO
  • Jeremy Chadwick, Ph.D., Chief Operating Officer
  • Ellen Chiniara, JD, Chief Legal Officer and Corporate Secretary
  • Jared Gollob, MD, Chief Medical Officer
  • Bruce Jacobs, CFA, MBA, Chief Financial Officer
  • Karen Weisbach, Head of People and Culture
  • Juliet Williams, Ph.D., Head of Research
  • Bruce Booth, DPhil, Chairman and Co-Founder
  • Felix J. Baker, PhD, Lead Independent Director
  • Jeff Albers, JD, MBA,
  • Pamela Esposito, PhD,
  • Gorjan Hrustanovic, PhD,
  • John Maraganore, PhD,
  • Leigh Morgan,
  • Victor Sandor, MDCM,
  • Elena Ridloff, CFA,

Last updated: 2024-12-31

Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated logo
Market Cap: High
Employees: Lowest

Kyprolis, Evomela, Veklury, Teriparatide, Vaxneuvance, Pneumosil, Rylaze, Nexterone, Zulresso, Noxafil-IV

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company focused on developing or acquiring technologies to aid pharmaceutical companies in discovering and developing medicines. The company's commercial programs include treatments for multiple myeloma, COVID-19, osteoporosis, invasive diseases, childhood pneumonia, and acute lymphoblastic leukemia.

Tags: biopharmaceutical, commercial programs, disease treatment, medicine development, pharmaceutical technology

Symbol: LGND

Recent Price: $105.76

Industry: Biotechnology

CEO: Mr. Todd C. Davis Ph.D.

Sector: Healthcare

Employees: 58

Address: 5980 Horton Street, EmeryVille, CA 94608

Phone: 858 550 7500

Last updated: 2024-12-31

Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. logo
Market Cap: High
Employees: Low

Re Sure Sealant; DEXTENZA; OTX-TKI; OTX-TIC; OTX-CSI

Ocular Therapeutix is a biopharmaceutical company that develops and commercializes therapies for eye diseases using bioresorbable hydrogel-based technology, offering products like Re Sure Sealant and DEXTENZA.

Tags: biopharmaceutical, eye care, hydrogel, ophthalmic devices, ophthalmology, therapy

Symbol: OCUL

Recent Price: $8.35

Industry: Biotechnology

CEO: Dr. Pravin U. Dugel M.D.

Sector: Healthcare

Employees: 267

Address: 24 Crosby Drive, Bedford, MA 01730

Phone: 781 357 4000

Leadership

  • Pravin U. Dugel, MD, Executive Chairman, President and CEO
  • Karen-Leigh Edwards, PhD, MBA, Chief Operations Officer
  • Peter Jarrett, PhD, Chief Technical Officer
  • Donald Notman, Chief Financial Officer and Chief Operating Officer
  • Nadia K. Waheed, MD, MPH, Chief Medical Officer
  • Jeffrey S. Heier, MD, Chief Scientific Officer
  • Steve Meyers, Chief Commercial Officer
  • Tracy Smith, Vice President, Human Resources
  • Sanjay Nayak, MBBS, PhD, Chief Strategy Officer
  • Peter K. Kaiser, MD, Chief Development Officer
  • Todd Anderman, JD, Chief Legal Officer and Corporate Secretary
  • Charles Warden, Lead Independent Director
  • Adrienne Graves, PhD, Director
  • Leslie Williams, Director
  • Richard Lindstrom, MD, Director
  • Seung Suh Hong, PhD, Director
  • Merilee Raines, Director

Last updated: 2024-12-31

Pacira BioSciences, Inc.

Pacira BioSciences, Inc. logo
Market Cap: Medium
Employees: Medium

EXPAREL, ZILRETTA, iovera

Pacira Bio Sciences, Inc. offers non-opioid pain management and regenerative health solutions. Products include EXPAREL, ZILRETTA, and the iovera system. The company focuses on drug delivery technology with a proprietary multivesicular liposome system.

Tags: drug delivery, healthcare, non-opioid, pain management, regenerative health

Symbol: PCRX

Recent Price: $18.94

Industry: Drug Manufacturers - Specialty & Generic

CEO: Mr. Frank D. Lee

Sector: Healthcare

Employees: 711

Address: 5401 West Kennedy Boulevard, Tampa, FL 33609

Phone: 813 553 6680

Leadership

  • Frank D. Lee, Chief Executive Officer and member of the Board of Directors
  • Paul J Hastings, Chair of the Board of Directors
  • Marcelo Bigal, MD, PhD, President and Chief Executive Officer of Ventus Therapeutics
  • Laura Brege, Former CEO of Nodality, Inc.
  • Abraham Ceesay, Chief Executive Officer of Rapport Therapeutics
  • Chris Christie, Director
  • Mark I. Froimson, MD, Principal at Riverside Health Advisors
  • Mark Kronenfeld, MD, Chairman of Anesthesiology at Maimonides Medical Center
  • Andreas Wicki, PhD, Chief Executive Officer of HBM Healthcare Investments AG
  • Michael Yang, Former Chief Executive Officer of ViaCyte
  • Alethia Young, Chief Financial Officer of Bicycle Therapeutics

Last updated: 2024-12-31

Repligen Corporation

Repligen Corporation logo
Market Cap: Highest
Employees: High

bioprocessing technologies and systems

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing worldwide, offering products like Protein A ligands, chromatography columns, ELISA test kits, and filtration products.

Tags: ELISA test kits, Protein A ligands, biologics purification, bioprocessing, chromatography, filtration systems

Symbol: RGEN

Recent Price: $143.81

Industry: Medical - Instruments & Supplies

CEO: Mr. Olivier Loeillot

Sector: Healthcare

Employees: 1783

Address: Building 1, Waltham, MA 02453

Phone: 781 250 0111

Leadership

  • Mark A. Gambino, President and CEO
  • Pradeep K. Gohil, Chief Financial Officer
  • Matthew B. Wrobel, Chief Technology Officer
  • Claudia A. Grunewald, Director of Quality Assurance
  • Mickey R. Perry, Chief Operating Officer
  • Paul C. Miller, General Counsel and Secretary
  • James J. O'Brien, Chairman of the Board
  • Diane Williams, Board Member
  • Charles A. Jamieson, Board Member
  • Rebecca D. Faulkner, Board Member

Last updated: 2024-12-31

Relay Therapeutics, Inc.

Relay Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

RLY-4008, RLY-2608, RLY-1971

Relay Therapeutics, Inc. is a clinical-stage company that focuses on precision medicine in oncology and genetic diseases by transforming the drug discovery process. Their leading products include small molecule inhibitors for advanced cancer treatment.

Tags: FGFR2, PI3Ka, Src homology, clinical-stage, drug discovery, genetic diseases, oncology, precision medicines, small molecule inhibitors

Symbol: RLAY

Recent Price: $4.18

Industry: Biotechnology

CEO: Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS

Sector: Healthcare

Employees: 323

Address: 399 Binney Street, Cambridge, MA 02139

Phone: 617 370 8837

Last updated: 2024-12-31